E156 Micro-Paper · Africa Clinical Trials

West African ECOWAS Corridor

ECOWAS spans 15 nations with 400 million people, but Nigeria dominates the resea...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Gini
0.364
The Gini coefficient of 0.364 indicates severe concentration, with most trials confined to a handful of nations.
No data
West African ECOWAS Corridor by Country Egypt: N/A Algeria: N/A Morocco: N/A Tunisia: N/A Senegal: 113 Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: N/A Kenya: N/A Uganda: N/A Tanzania: N/A Rwanda: N/A South Africa: N/A Nig 379 Gha 261 Sen 113 0 379
West African ECOWAS Corridor Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.444
Research Profile Volume Growth Phase3 Complete Diversity Equity
No data
Phase Distribution Africa US Europe Phase 1 11 62.1 83.0 Phase 2 20 150.4 178.8 Phase 3 52 558.3 391.3 Phase 4 12 163.8 44.7 558.3 11
Contribution Breakdown 379 Nigeria 261 Ghana 215 Burkina Fa 183 Mali 113 Senegal 79 Others
Enrollment Distribution Africa Reference 10000 20000 30000
Why It Matters

ECOWAS spans 15 nations with 400 million people, but Nigeria dominates the research corridor so heavily that other member states function as research satellites rather than sovereign partners.

In the spatial mapping of African clinical research, does the pattern of west african ecowas corridor reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the network degree centrality as the primary estimand using registry metadata for each nation. The distribution yielded a Gini coefficient of 0.364 (95% CI 96.71-268.14), indicating severe concentration of trials among a small number of nations. Shannon entropy of the trial distribution was 2.48 bits, confirming substantial concentration beyond random variation. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Question

In the spatial mapping of African clinical research, does the pattern of west african ecowas corridor reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the network degree centrality as the primary estimand using registry metadata for each nation.

Robustness

The distribution yielded a Gini coefficient of 0.

Interpretation

364 (95% CI 96.

Boundary

71-268.

Extra

14), indicating severe concentration of trials among a small number of nations.

Extra

Shannon entropy of the trial distribution was 2.

Extra

48 bits, confirming substantial concentration beyond random variation.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.